Logo image of VXRT

VAXART INC (VXRT) Stock Fundamental Analysis

NASDAQ:VXRT - Nasdaq - US92243A2006 - Common Stock - Currency: USD

0.32  -0.11 (-25.06%)

After market: 0.3251 +0.01 (+1.59%)

Fundamental Rating

2

Taking everything into account, VXRT scores 2 out of 10 in our fundamental rating. VXRT was compared to 558 industry peers in the Biotechnology industry. VXRT has a bad profitability rating. Also its financial health evaluation is rather negative. VXRT is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VXRT has reported negative net income.
VXRT had a negative operating cash flow in the past year.
In the past 5 years VXRT always reported negative net income.
In the past 5 years VXRT always reported negative operating cash flow.
VXRT Yearly Net Income VS EBIT VS OCF VS FCFVXRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

VXRT has a Return On Assets (-36.66%) which is comparable to the rest of the industry.
With a Return On Equity value of -127.41%, VXRT perfoms like the industry average, outperforming 41.04% of the companies in the same industry.
Industry RankSector Rank
ROA -36.66%
ROE -127.41%
ROIC N/A
ROA(3y)-66.71%
ROA(5y)-50.62%
ROE(3y)-117.91%
ROE(5y)-83.49%
ROIC(3y)N/A
ROIC(5y)N/A
VXRT Yearly ROA, ROE, ROICVXRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

VXRT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VXRT Yearly Profit, Operating, Gross MarginsVXRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

1

2. Health

2.1 Basic Checks

VXRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VXRT has more shares outstanding
Compared to 5 years ago, VXRT has more shares outstanding
VXRT has a better debt/assets ratio than last year.
VXRT Yearly Shares OutstandingVXRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
VXRT Yearly Total Debt VS Total AssetsVXRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -5.12, we must say that VXRT is in the distress zone and has some risk of bankruptcy.
VXRT has a Altman-Z score of -5.12. This is comparable to the rest of the industry: VXRT outperforms 40.14% of its industry peers.
VXRT has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, VXRT is in line with its industry, outperforming 42.47% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -5.12
ROIC/WACCN/A
WACC9.59%
VXRT Yearly LT Debt VS Equity VS FCFVXRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

VXRT has a Current Ratio of 0.64. This is a bad value and indicates that VXRT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.64, VXRT is not doing good in the industry: 91.22% of the companies in the same industry are doing better.
VXRT has a Quick Ratio of 0.64. This is a bad value and indicates that VXRT is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.64, VXRT is doing worse than 90.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.64
Quick Ratio 0.64
VXRT Yearly Current Assets VS Current LiabilitesVXRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.06% over the past year.
Looking at the last year, VXRT shows a very strong growth in Revenue. The Revenue has grown by 433.37%.
VXRT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.72% yearly.
EPS 1Y (TTM)49.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)433.37%
Revenue growth 3Y217.11%
Revenue growth 5Y23.72%
Sales Q2Q%857.18%

3.2 Future

VXRT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.50% yearly.
Based on estimates for the next years, VXRT will show a very strong growth in Revenue. The Revenue will grow by 30.95% on average per year.
EPS Next Y15.8%
EPS Next 2Y-6.58%
EPS Next 3Y-9.17%
EPS Next 5Y0.5%
Revenue Next Year-37.03%
Revenue Next 2Y-48.87%
Revenue Next 3Y-34.32%
Revenue Next 5Y30.95%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VXRT Yearly Revenue VS EstimatesVXRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M 250M
VXRT Yearly EPS VS EstimatesVXRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VXRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VXRT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VXRT Price Earnings VS Forward Price EarningsVXRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VXRT Per share dataVXRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

VXRT's earnings are expected to decrease with -9.17% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.58%
EPS Next 3Y-9.17%

More info and screens

0

5. Dividend

5.1 Amount

VXRT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VAXART INC

NASDAQ:VXRT (7/7/2025, 10:34:23 PM)

After market: 0.3251 +0.01 (+1.59%)

0.32

-0.11 (-25.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-07 2025-08-07
Inst Owners12.07%
Inst Owner Change0%
Ins Owners1.03%
Ins Owner Change52.03%
Market Cap73.03M
Analysts86.67
Price Target3.06 (856.25%)
Short Float %7.53%
Short Ratio3.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.06%
Min EPS beat(2)31.15%
Max EPS beat(2)50.98%
EPS beat(4)3
Avg EPS beat(4)-26.88%
Min EPS beat(4)-230.84%
Max EPS beat(4)50.98%
EPS beat(8)7
Avg EPS beat(8)-4.36%
EPS beat(12)10
Avg EPS beat(12)-1.05%
EPS beat(16)13
Avg EPS beat(16)-0.9%
Revenue beat(2)1
Avg Revenue beat(2)43%
Min Revenue beat(2)-28.31%
Max Revenue beat(2)114.31%
Revenue beat(4)3
Avg Revenue beat(4)1682.62%
Min Revenue beat(4)-28.31%
Max Revenue beat(4)6175.49%
Revenue beat(8)7
Avg Revenue beat(8)1313.72%
Revenue beat(12)7
Avg Revenue beat(12)849.62%
Revenue beat(16)7
Avg Revenue beat(16)625.02%
PT rev (1m)-35.71%
PT rev (3m)-35.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.83%
EPS NY rev (1m)3.44%
EPS NY rev (3m)15.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-82.09%
Revenue NY rev (1m)38.91%
Revenue NY rev (3m)323.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.54
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.94
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.21
BVpS0.2
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.66%
ROE -127.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.71%
ROA(5y)-50.62%
ROE(3y)-117.91%
ROE(5y)-83.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.2%
Cap/Sales 1.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.64
Quick Ratio 0.64
Altman-Z -5.12
F-Score5
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)64.4%
Cap/Depr(5y)72.15%
Cap/Sales(3y)3209.1%
Cap/Sales(5y)2046.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y15.8%
EPS Next 2Y-6.58%
EPS Next 3Y-9.17%
EPS Next 5Y0.5%
Revenue 1Y (TTM)433.37%
Revenue growth 3Y217.11%
Revenue growth 5Y23.72%
Sales Q2Q%857.18%
Revenue Next Year-37.03%
Revenue Next 2Y-48.87%
Revenue Next 3Y-34.32%
Revenue Next 5Y30.95%
EBIT growth 1Y30.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.76%
OCF growth 3YN/A
OCF growth 5YN/A